Device for local and/or regional delivery employing liquid formulations of therapeutic agents
View Patent ↗Medical devices may be utilized for local and regional therapeutic agent delivery. These therapeutic agents or compounds may reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including restenosis, vulnerable plaque, and atherosclerosis in type 2 diabetic patients. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned.
1. A drug delivery device comprising:
an expandable member having an external surface and configured such that the external surface makes contact with surrounding tissue when the expandable member is expanded; and
a liquid formulation of a therapeutic agent affixed to the external surface of the expandable member and configured for release into surrounding tissue when the external surface of the expandable member makes contact with the expandable member, the liquid formulation comprising rapamycin in a pharmaceutically effective dosage, ethanol in a residual concentration of about 1.57 percent by weight, vitamin E TPGS in an amount of about 6.55 percent by weight and water in an amount of about 90.51 percent by weight, the liquid formulation comprising a final solution of rapamycin in the range from about 4mg/ml to about 15 mg/ml.
2. The drug delivery device according to claim 1 , wherein the expandable member comprises a stent.
3. The drug delivery device according to claim 1 , wherein the expandable member comprises a balloon.
4. The drug delivery device according to claim 1 , wherein the rapamycin comprises sirolimus.
5. The drug delivery device according to claim 4 , wherein the rapamycin comprises CCI-779.